T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

T-Cell Metabolism, Immunodeficiency and Human Disease

Adoptive T Cell Therapy Applications

CAR-T Cell Toxicity and Safety Profiles

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Immunotherapy combined with BCG vaccine drastically lowers tuberculosis relapse risk

Tuberculosis (TB) remains one of the world's leading causes of death, and preventing post-treatment relapse continues to be a major worldwide health challenge.

17 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Rituximab alters T-cell metabolism in patients with nephrotic syndrome

Nephrotic syndrome is caused when the filtering system in the kidneys is damaged, allowing large amounts of protein to leak into the urine.

10 Sep 2026

Gut infection leaves long-lasting immune ‘memories’ at the brain’s borders in mice

In mice, intestinal infections reshaped dural CD4+ T-cell populations and seeded the brain’s outer meningeal border with antigen-specific memory cells that persisted for months and mounted rapid recall responses to bloodborne antigens. Oral priming was associated with reduced Salmonella spread to the brain and modest cross-protection in an engineered shared-antigen Candida model, although the researchers could not definitively prove that dural CD4+ T cells alone caused the protection.

9 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Discover how LumiPore improves intracellular delivery with gentle, high-efficiency transfection for drug discovery and cell therapy research.

From Trince 8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Scientists traced a hidden immune route that may worsen tau-linked brain damage

In a mouse model of tauopathy, conventional type 1 dendritic cells (cDC1s) cross-presented brain-derived antigens in deep cervical lymph nodes, priming CD8+ T cells that accumulated in the brain and promoted neurodegeneration. Disrupting cDC1s or their cross-presentation activity reduced CD8+ T-cell infiltration and protected against neuronal loss, while human primary tauopathy samples also showed increased brain CD8+ T cells, although cDC1 involvement in humans remains unconfirmed.

6 Sep 2026

Pig kidney xenotransplantation offers a bridge for patients awaiting human donor kidneys

In January 2026, Tim Andrews, who had received a genetically edited pig kidney in January 2025, became the recipient of a human kidney.

3 Sep 2026

Microscopic peptide droplets reduce colorectal tumor growth in mice

Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed microscopic peptide droplets that deliver large amounts of gene-silencing molecules into cancer and immune cells, reducing the growth of hard-to-treat colorectal tumours by about 67 per cent in mice.

3 Sep 2026

New optical imaging reveals metabolic activity of individual immune cells

A routine blood sample contains a diverse collection of immune cells that can reveal important clues about health and disease.

2 Sep 2026

Shared biological pathways may explain chronic fatigue across diseases

A shared biological secret that helps explain chronic exhaustion in conditions including long Covid and PTSD has been discovered by researchers at the University of East Anglia and Oxford BioDynamics.

2 Sep 2026

UNC researcher wins major grant to study the role of endoplasmic reticulum in T-cell metabolism

Jessica Thaxton, PhD, MsCR, associate professor in the Department of Cell Biology and Physiology at the UNC School of Medicine and co-leader of the Cancer Cell Biology Research Program at UNC Lineberger Comprehensive Cancer Center, has been awarded a prestigious $700,000 grant from the Mathers Foundation to support research into the role of the endoplasmic reticulum in T-cell metabolism and cancer development.

1 Sep 2026

Immunotherapy shows potential for treating rising gynecological tumors

Gynecological tumors, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC), represent a significant global health burden for women.

1 Sep 2026

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

28 Aug 2026